IL19 (Interleukin 19)

Notably, pancreatic IL-19 mRNA expression was significantly upregulated in CP, suggesting an endogenous compensatory mechanism. IL-19 deficiency worsens ethanol/LPS-induced chronic pancreatitis, indicating that endogenous IL-19 protects against inflammation and fibrosis and may serve as a therapeutic target.

These findings establish TOPK as a central regulator of solar UV-induced skin carcinogenesis, partially via modulation of IL19 signaling and fibroblast activation. Targeting TOPK may offer a novel strategy for the prevention and treatment of NMSC.

IL-19 is a promising theranostic target for reversing immunosuppression and restricting the invasive activity of chemoresistant GBM cells.

The in-vivo and in-vitro studies have also reflected that upregulation of IL-19 enhances tumor development and affects clinical outcomes in BC patients through several pathways including the JAK TAT signalling pathway. Overall, our study indicates that IL-19 increases tumour growth and that inhibiting it in addition to standard treatments will greatly improve BC patient's therapeutic responses.